LENZ — Lenz Therapeutics Cashflow Statement
0.000.00%
- $303.20m
- $10.85m
- $19.09m
Annual cashflow statement for Lenz Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -70.8 | -101 | -125 | -49.8 | -82.1 |
| Depreciation | |||||
| Non-Cash Items | 19.7 | 17.9 | 71.5 | 3.41 | 5.14 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -2.5 | -7.21 | -39.2 | -13.1 | 7.53 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -52.9 | -88 | -90 | -59.4 | -69.2 |
| Capital Expenditures | -5.74 | -6.59 | -10.9 | -0.468 | -0.827 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -235 | 237 | -154 | -74.8 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -5.74 | -242 | 226 | -154 | -75.7 |
| Financing Cash Flow Items | — | -0.079 | -0.067 | 115 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 417 | 0.597 | 0.19 | 199 | 150 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 359 | -329 | 137 | -14.9 | 4.91 |